Literature DB >> 3317054

High-dose corticosteroids in patients with the adult respiratory distress syndrome.

G R Bernard1, J M Luce, C L Sprung, J E Rinaldo, R M Tate, W J Sibbald, K Kariman, S Higgins, R Bradley, C A Metz.   

Abstract

Corticosteroids are widely used as therapy for the adult respiratory distress syndrome (ARDS) without proof of efficacy. We conducted a prospective, randomized, double-blind, placebo-controlled trial of methylprednisolone therapy in 99 patients with refractory hypoxemia, diffuse bilateral infiltrates on chest radiography and absence of congestive heart failure documented by pulmonary-artery catheterization. The causes of ARDS included sepsis (27 percent), aspiration pneumonia (18 percent), pancreatitis (4 percent), shock (2 percent), fat emboli (1 percent), and miscellaneous causes or more than one cause (42 percent). Fifty patients received methylprednisolone (30 mg per kilogram of body weight every six hours for 24 hours), and 49 received placebo according to the same schedule. Serial measurements were made of pulmonary shunting, the ratio of partial pressure of arterial oxygen to partial pressure of alveolar oxygen, the chest radiograph severity score, total thoracic compliance, and pulmonary-artery pressure. We observed no statistical differences between groups in these characteristics upon entry or during the five days after entry. Forty-five days after entry there were no differences between the methylprednisolone and placebo groups in mortality (respectively, 30 of 50 [60 percent; 95 percent confidence interval, 46 to 74] and 31 of 49 [63 percent; 95 percent confidence interval, 49 to 77]; P = 0.74) or in the reversal of ARDS (18 of 50 [36 percent] vs. 19 of 49 [39 percent]; P = 0.77). However, the relatively wide confidence intervals in the mortality data make it impossible to exclude a small effect of treatment. Infectious complications were similar in the methylprednisolone group (8 of 50 [16 percent]) and the placebo group (5 of 49 [10 percent]; P = 0.60). Our data suggest that in patients with established ARDS due to sepsis, aspiration, or a mixed cause, high-dose methylprednisolone does not affect outcome.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3317054     DOI: 10.1056/NEJM198712173172504

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  163 in total

Review 1.  The pulmonary physician in critical care - part 9: non-ventilatory strategies in ARDS.

Authors:  J Cranshaw; M J D Griffiths; T W Evans
Journal:  Thorax       Date:  2002-09       Impact factor: 9.139

Review 2.  The pulmonary physician and critical care. 4. A new look at the pulmonary circulation in acute lung injury.

Authors:  G A Fox; D G McCormack
Journal:  Thorax       Date:  1992-09       Impact factor: 9.139

Review 3.  The pulmonary physician and critical care. 3. Pharmacotherapy in lung injury.

Authors:  M Messent; M J Griffiths
Journal:  Thorax       Date:  1992-08       Impact factor: 9.139

Review 4.  [Corticosteroid administration for acute respiratory distress syndrome : therapeutic option?].

Authors:  P Möhnle; J Briegel
Journal:  Anaesthesist       Date:  2012-04       Impact factor: 1.041

Review 5.  The use of radionuclide techniques in the assessment of alveolar-capillary membrane permeability on the intensive care unit.

Authors:  D N Hunter; C J Morgan; T W Evans
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

6.  Steroids are part of rescue therapy in ARDS patients with refractory hypoxemia: yes.

Authors:  Thomas Bein; Josef Briegel; Djillali Annane
Journal:  Intensive Care Med       Date:  2016-02-16       Impact factor: 17.440

Review 7.  The adult respiratory distress syndrome.

Authors:  N F Voelkel
Journal:  Klin Wochenschr       Date:  1989-06-01

8.  Neutrophils promote alveolar epithelial regeneration by enhancing type II pneumocyte proliferation in a model of acid-induced acute lung injury.

Authors:  Andrew J Paris; Yuhong Liu; Junjie Mei; Ning Dai; Lei Guo; Lynn A Spruce; Kristin M Hudock; Jacob S Brenner; William J Zacharias; Hankun D Mei; April R Slamowitz; Kartik Bhamidipati; Michael F Beers; Steven H Seeholzer; Edward E Morrisey; G Scott Worthen
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-09-30       Impact factor: 5.464

Review 9.  Prevention and therapy of the adult respiratory distress syndrome.

Authors:  B Temmesfeld-Wollbrück; D Walmrath; F Grimminger; W Seeger
Journal:  Lung       Date:  1995       Impact factor: 2.584

10.  The acute respiratory distress syndrome: definitions, severity and clinical outcome. An analysis of 101 clinical investigations.

Authors:  P Krafft; P Fridrich; T Pernerstorfer; R D Fitzgerald; D Koc; B Schneider; A F Hammerle; H Steltzer
Journal:  Intensive Care Med       Date:  1996-06       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.